The Efficacy of Oxybutynin Chloride OROS in Patient-Reported Outcomes With Dose Escalation in Korean Overactive Bladder Patients
Phase of Trial: Phase IV
Latest Information Update: 13 Sep 2013
At a glance
- Drugs Oxybutynin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutica
- 20 May 2009 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
- 20 May 2009 Actual initiation date changed from Sep 2007 to Sep 2006 as reported by ClinicalTrials.gov.
- 20 May 2009 Actual patient number (320) added as reported by ClinicalTrials.gov.